Formulation and Drug Delivery

Merck: Biosimilar Makers Likely to Target New Patients

February 04, 2016

Although switching has occurred in European markets for some biosimilars, most biosimilar manufacturers will focus on securing new users, according to Merck.

ViaCyte Enters Clinical Trials for Type 1 Diabetes Treatment

February 04, 2016

ViaCyte and Janssen Biotech have entered Phase I/Phase II clinical trials for VC-01, a candidate treatment for the treatment of type 1 diabetes.

Going Small to Achieve Commercial-Scale Success

February 02, 2016

Scale-down modeling is instrumental in supporting the development of downstream biopharma manufacturing processes.

Biosimilars Forum Launches Education Initiative

February 01, 2016

The Biosimilars Forum launched Partnership for Biosimilars Education and Access, an education initiative raising awareness of biosimilars in the US.

Keeping It Simple: Collaborating for Success in Drug Delivery

February 01, 2016

For successful partnerships, it’s important to take a long-term view, focus on simple designs, and address potential payer concerns up front.

Assessing Antibody-Dependent Cell-Mediated Cytotoxicity

February 01, 2016

The reporter bioassay, used to evaluate ADCC activity of therapeutic antibodies, complements the classical ADCC assay.

Hermes Pharma Adds Hot Melt Coating Capability

January 28, 2016

PTSM: Pharmaceutical Technology Sourcing and Management

Hermes Pharma has commercially implemented hot-melt coating (HMC) technology at its production facility.

The collaboration will focus on development of novel molecules using SMARTag technology to couple different therapeutic modalities.